Gómez, F. (F.)

Filtering

2014 - 201912020 - 20222

Settings

Author search.filters.isAuthorOfPublication.7fab45f8-71de-47cf-914b-fc67f021301a

Search Results

Now showing 1 - 3 of 3
  • Thumbnail Image
    A multicentre, international, observational study on transarterial chemoembolisation in colorectal cancer liver metastases: Design and rationale of CIREL
    (Elsevier, 2020) Pellerin, O. (Olivier); Kaufmann, N. (Nathalie); Iezzi, R. (Roberto); Arnold, D. (Dirk); Taieb, J. (Julien); Bauer, R. (Robert); Sangro, B. (Bruno); Maleux, G. (Geert); Nordlund, A. (Anders); Baere, T. (T.) de; Helmberger, T. (Thomas); Pereira, P.L. (Philippe L.); Prenen, H. (Hans); Zeka, B. (Bleranda); Gómez, F. (F.)
    Background: About 70–80% of patients with colorectal liver metastases appear as ineligible for a curative treatment approach. Transarterial chemoembolisation (TACE) using irinotecan-eluting beads has emerged as a promising treatment option in cases with irresectable liver metastases. Despite being in clinical practice for years, little is known about the treatment characteristics and outcomes when used as per routine hospital practice. Methods: Patients with hepatic metastases from colorectal cancer origin, admitted to contributing centres to receive TACE with drug-eluting LifePearl® Microspheres loaded with irinotecan, as part of their standard care, will be consecutively added to the registry. Data will be collected until the end of study, loss to follow-up or death. Primary endpoint is the characterisation of the treatment usage at the selected sites in Europe. Secondary endpoints include outcome parameters, safety and toxicity, as well as quality of life. Conclusion and AIMS: This multicentre, international, prospective observational study conducted in European centres plans to collect real-life data. This data will form an evidence-base from which conclusions can be drawn on how to improve patient selection and optimise treatment protocols when treating with TACE using irinotecan-eluting microspheres.
  • Thumbnail Image
    Factors influencing seasonal patterns of relapse in anti-TNF psoriatic responders after temporary drug discontinuation
    (Wiley, 2014) Ruano, J. (J.); Jimenez-Puya, R. (R.); Salido-Vallejo, R. (Rafael); Casas, E. (E.); Moreno-Giménez, J.C. (J. C.); Espejo-Alvarez, J. (J.); Rodríguez-Martínez, A. (Alicia); Vélez, A. (Antonio); Isla-Tejera, B. (B.); Gómez, F. (F.)
    The intra- and inter-variability observed with regard to the extent, duration and severity of psoriasis is the result of the interaction of genetic and environmental factors. In clinical practice, once efficacy has been achieved with anti-Tumor Necrosis Factor (TNF) drugs, temporary suspension of such treatment is followed by a disease-free period. To date, the factors that condition the differences in the duration of remission obtained in clinical setting are not well understood. One of the environmental factors that might modulate the clinical expression of psoriasis is seasonal changes.2 Seasonal variations in solar radiation, degree of humidity or temperature may have a biological effect on the skin3-5 and immune system.6, 7
  • Thumbnail Image
    Differences In Linear Epitopes Of Ara h 9 Recognition In Peanut Allergic And Tolerant, Peach Allergic Patients
    (2022) Martínez-Botas, J. (J.); Sánchez-Ruano, L. (L.); Goikoetxea-Lapresa, M.J. (María José); Fernández-Lozano, C. (C.); Gómez, F. (F.); Ferrer-Cardona, M. (Marta); Gómez, F. (F.)
    Background: Peanut-allergic patients from the Mediterranean region are predominantly sensitized to the lipid transfer protein (LTP) Ara h 9, and the peach LTP Pru p 3 seems to be the primary sensitizer. However, LTP sensitization in peanut allergy is not a predictive marker for clinically relevant symptoms. Objective: We aimed to identify sequential epitopes of IgE and IgG4 from Pru p 3 and Ara h 9 in peach-allergic patients sensitized to peanuts. We also sought to determine the differences in IgE and IgG4 binding between patients who had developed peanut allergy and those tolerating peanuts. Methods: A total of 46 peach-allergic patients sensitized to peanuts were selected. A total of 35 patients were allergic to peanuts (peanut-allergic group) and 11 were tolerant to peanuts (peanut-tolerant group). We measured sIgE and sIgG4 in peanut, peach, and their recombinant allergen (Ara h 1, Ara h 2, Ara h 3, Ara h 8, and Ara h 9) with fluorescence enzyme immunoassay. We examined the IgE and IgG4 binding to sequential epitopes using a peptide microarray corresponding to linear sequences of the LTPs Ara h 9 and Pru p 3 with a library of overlapping peptides with a length of 20 amino acids (aa) and an offset of 3 aa. Results: The frequency and the intensity of IgE recognition of Ara h 9 and Pru p 3 peptides were higher in the peanut-tolerant group than in the peanut-allergic group. We found four Ara h 9 peptides (p4, p14, p21, and p25) and four Pru p 3 peptides (p1, p3, p21, and p24) with a significantly elevated IgE recognition in peanut-tolerant patients. Only one peptide of Ara h 9 (p4) recognized by IgG4 was significantly elevated in the peanut-tolerant group. The IgG4/IgE ratio of Ara h 9 peptide 4 was significantly higher in peanut-tolerant patients than in peanut-allergic patients, while no significant differences were observed in the IgG4/IgE ratio of this peptide in Pru p 3. Conclusion: Although we found significant differences in IgE and IgG4 recognition of Ara h 9 and Pru p 3 between peanut-tolerant and peanut-allergic patients (all of whom were allergic to peach), polyclonal IgE peptide recognition of both LTPs was observed in peach-allergic patients tolerating peanuts. However, the IgG4 blocking antibodies against Ara h 9 peptide 4 could provide an explanation for the absence of clinical reactivity in peanut-tolerant peach-allergic patients. Further studies are needed to validate the usefulness of IgG4 antibodies against Ara h 9 peptide 4 for peanut allergy diagnosis.